Correction to: Curr Hematol Malig Rep (2018) 13:383–395
The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below.
Jedd D. Wolchok is a consultant for Adaptive Biotech, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, Beigene, Bristol Myers Squibb, Celgene, Chugai, Elucida, Eli Lilly, F Star, Genentech, Imvaq, Kleo Pharma, MedImmune, Merck, Neon Therapuetics, Ono, Polaris Pharma, Polynoma, Psioxus, Puretech, Recepta, Trienza, Sellas Life Sciences, Serametrix, Surface Oncology, and Syndax and has received research support from Bristol Myers Squibb, Medimmune, Merck Pharmaceuticals, and Genentech. Equity in: Potenza Therapeutics, Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq, Beigene, and Trieza. Roberta Zappasodi and Taha Merghoub declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at https://doi.org/10.1007/s11899-018-0471-9
Rights and permissions
About this article
Cite this article
Zappasodi, R., Wolchok, J.D. & Merghoub, T. Correction to: Strategies for Predicting Response to Checkpoint Inhibitors. Curr Hematol Malig Rep 14, 62 (2019). https://doi.org/10.1007/s11899-018-0488-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11899-018-0488-0